

APPLY NOW

2021 Microbial Pathogenesis in Alzheimer's Disease Grant
Applications Close September 21



Up to \$1.7 million in grant funding



Individual grants of up to \$250,000

IDSA 20
EXCELLENCE



Cutting Edge: Proangiogenic Properties of Alternatively Activated Dendritic Cells

Elena Riboldi, Tiziana Musso, Emanuela Moroni, Chiara Urbinati, Sergio Bernasconi, Marco Rusnati, Luciano Adorini, Marco Presta and Silvano Sozzani

This information is current as of September 16, 2021.

J Immunol 2005; 175:2788-2792; ;

doi: 10.4049/jimmunol.175.5.2788

<http://www.jimmunol.org/content/175/5/2788>

References This article **cites 21 articles**, 7 of which you can access for free at:
<http://www.jimmunol.org/content/175/5/2788.full#ref-list-1>

Why *The JI*? Submit online.

- **Rapid Reviews! 30 days*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

**average*

Subscription Information about subscribing to *The Journal of Immunology* is online at:
<http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at:
<http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
<http://jimmunol.org/alerts>

The Journal of Immunology is published twice each month by
The American Association of Immunologists, Inc.,
1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2005 by The American Association of
Immunologists All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.



Cutting Edge: Proangiogenic Properties of Alternatively Activated Dendritic Cells¹

Elena Riboldi,* Tiziana Musso,[†] Emanuela Moroni,* Chiara Urbinati,* Sergio Bernasconi,[‡] Marco Rusnati,* Luciano Adorini,[§] Marco Presta,* and Silvano Sozzani^{2*}

Angiogenesis plays an important role in tissue remodeling and repair during the late phase of inflammation. In the present study, we show that human dendritic cells (DC) that matured in the presence of anti-inflammatory molecules such as calcitriol, PGE₂, or IL-10 (alternatively activated DC) selectively secrete the potent angiogenic cytokine vascular endothelial growth factor (VEGF) isoforms VEGF₁₆₅ and VEGF₁₂₁. No VEGF production was observed in immature or classically activated DC. Also, the capacity to produce VEGF was restricted to the myeloid DC subset. When implanted in the chick embryo chorioallantoic membrane, alternatively activated DC elicit a marked angiogenic response, which is inhibited by neutralizing anti-VEGF Abs and by the VEGFR-2 inhibitor SU5416. Therefore, alternatively activated DC may contribute to the resolution of the inflammatory reaction by promoting VEGF-induced angiogenesis. The Journal of Immunology, 2005, 175: 2788–2792.

Dendritic cells (DC)³ are professional APC that play a crucial role in the onset and regulation of acquired immunity. The number of tissue DC rapidly increases during inflammation, and DC participate to the regulation of the inflammatory reaction through the release of cytokines and chemokines (1).

The balance between pro- and anti-inflammatory signals present in the inflammatory microenvironment determines the phenotype and the behavior of the immune cells at the site of inflammation (2). APC such as macrophages activated by IFN- γ and proinflammatory signals (e.g., LPS and TNF- α) are characterized by proinflammatory and cytotoxic functions. Conversely, exposure of macrophages to anti-inflammatory molecules, such as IL-10, IL-13, IL-4, calcitriol, and glucocorticoids, induces an alternative program of activation characterized by a peculiar membrane phenotype and function (2).

Alternatively activated macrophages are devoid of proinflammatory and cytotoxic functions; instead, they express high levels of MHC class II molecules and are potent endocytic cells. Alternatively activated macrophages play a relevant role during the resolution phase of inflammation by producing cytokines (e.g., IL-10, TGF- β , and IL-1 receptor antagonist) and scavenging cellular debris. DC may also be alternatively activated and induced to express a different profile of cytokines and functions. For instance, alternatively activated DC (AA-DC) were shown to produce CCL18 and to possess tolerogenic activity (3).

The resolution phase of inflammation is characterized by enhanced angiogenesis. Newly formed blood vessels provide nutrients to growing tissues and allow traffic of immune cells. This process is sustained by the early production of angiogenic factors, including basic fibroblast growth factor (FGF) (FGF-2), TNF- α , some “ELR” chemokines, such as CXCL8, followed by the release of vascular endothelial growth factor (VEGF), whose production peaks several days after injury (4, 5).

In this study, we investigated the angiogenic properties of DC in vitro and in vivo. The results show that alternatively activated myeloid DC, but not classically activated DC, release relevant levels of biologically active VEGF and possess proangiogenic activity in vivo.

Materials and Methods

DC preparation and culture

Highly enriched blood monocytes were obtained from buffy coats (through the courtesy of the Centro Trasfusionale) by Ficoll and Percoll (Amersham Biosciences) gradients. DC were generated in vitro as described previously (6). DC maturation (10^6 DC/ml) was induced by incubation with 100 ng/ml LPS (*Escherichia coli* 055:B5; Sigma-Aldrich), 1/5000 dilution of *Staphylococcus aureus* Cowan I (SAC) (Calbiochem), 20 ng/ml TNF- α (BASF/Knoll), or CD40L-transfected J558 cells (1:4 ratio) for 24 h. Where indicated, DC were treated with 50 ng/ml human IL-10 (Schering-Plough), 50 ng/ml TGF- β 1 (PeproTech), 10^{-5} M PGE₂, or 10^{-6} M (unless otherwise specified) calcitriol (1,25-dihydroxyvitamin D₃) (Sigma-Aldrich). Peripheral blood DC were obtained from PBMC by magnetic sorting with blood DC Ag 1 and blood DC Ag 4 kits (Miltenyi Biotec) (6). Cytokines were detected using specific Duo-Set kits (R&D Systems). DC conditioned medium (10^6 cells/ml) were concentrated on

*Unit of General Pathology and Immunology, Department of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy; [†]Department of Microbiology, University of Turin, Turin, Italy; [‡]“Mario Negri” Institute for Pharmacological Research, Milan, Italy; and [§]Bioxell, Milan, Italy

Received for publication May 17, 2005. Accepted for publication June 29, 2005.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by the Associazione Italiana per la Ricerca sul Cancro, the Ministero dell’Istruzione Università e Ricerca, Cofin and Fibr, Association for International Cancer Research Grant 04-223, the Fondazione Berlucci, Istituto Superiore di Sanità

(Programma Oncotecnologico), and Centro d’Eccellenza per l’Innovazione Diagnostica e Terapeutica (IDET).

² Address correspondence and reprint requests Dr. Silvano Sozzani, Unit of General Pathology and Immunology, Department of Biomedical Sciences and Biotechnology, University of Brescia, Viale Europa 11, 25123 Brescia, Italy. E-mail address: sozzani@med.unibs.it

³ Abbreviations used in this paper: DC, dendritic cell; AA-DC, alternatively activated DC; FGF, fibroblast growth factor; VEGF, vascular endothelial growth factor; SAC, *Staphylococcus aureus* Cowan I; PAE-KDR, KDR-transfected porcine aortic endothelial; CAM, chorioallantoic membrane; CA-DC, classically activated DC.

Centricon YM-10 filters (Millipore), and 500 μg of proteins were subjected to 15% SDS-PAGE, followed by Western blotting using an anti-VEGF Ab (Santa Cruz Biotechnology). Immunoreactivity was detected using the SuperSignal West Pico Chemiluminescent Substrate (Pierce).

RT-PCR

Total RNA was purified with TRIzol (Invitrogen Life Technologies). RNA samples (1 μg) were reverse transcribed using the SuperScript II RNase H⁻ Reverse Transcriptase (Invitrogen Life Technologies). PCR were performed on cDNA samples using the following primers: hTNF- α forward, 5'-GTCTCCTACCAGACCAAGGTCAA-3', and hTNF- α reverse, 5'-CAAAGTAGACCTGCCAGACTCG-3'; hCXCL8 forward, 5'-CGATGTCAGTGCATATAAGACA-3', and hCXCL8 reverse, 5'-TGAATTCTCAGCCCTCTTCAAAA-3'; hIL-12p40 forward, 5'-CCAAATTCCTACTTCTC-3', and hIL-12p40 reverse, 5'-GTCTATTCCGTTGTGTC-3'; hFGF-2 forward, 5'-AAGCGCTGTACTGCAAAAACG-3', and hFGF-2 reverse, 5'-AACTGGTGTATTTCCTTGACCGGTA-3'; hVEGF forward, 5'-TGGATGCTATCAGCCGACGCT-3', and hVEGF reverse, 5'-TGTTTTTCAGGAA CATTACACG-3'; and h β -actin forward, 5'-GAAGAGCTACGAGCTG CCTGA-3', and h β -actin reverse 5'-TGATCTTCTGCTGGGTG-3'. Amplified products were subjected to electrophoresis on agarose gels and stained with ethidium bromide.

VEGFR-2 transfectants

VEGFR-2/KDR-transfected porcine aortic endothelial (PAE/KDR) cells (7) were kindly provided by Dr. S. Mitola (University of Brescia, Brescia, Italy). Serum-starved cells were incubated at 37°C for 15 min with DC conditioned medium. Western blots were performed using anti-phospho-ERK1/2 Ab (Santa Cruz Biotechnology).

Chicken embryo chorioallantoic membrane (CAM) assay

Untreated DC, DC treated with 100 ng/ml LPS, or DC treated with 100 ng/ml LPS in the presence of 10⁻⁶ M calcitriol for 6 h were washed, entrapped in a 3% alginate pellet (3- μl suspension, 40,000 cells/pellet), and placed on top of the CAM of fertilized White Leghorn chicken eggs on day 11 of incubation. After 72 h, blood vessels entering the pellet within the focal plane of the CAM were photographed at $\times 20$ magnification and counted (8). In some experiments, 200 ng/egg of a blocking anti-VEGF Ab (R&D Systems) or 300 ng/egg of SU5416 [3-[(2,4-dimethylpyrrol-5-yl)methylidene]-indolin-2-one] (Calbiochem-Merk) were added to DC-loaded pellets. Pellets containing vehicle alone were used as negative control.

Statistical analysis

Statistical significance between the experimental groups was determined using unpaired Student's *t* test or one-way ANOVA with Dunnett's post hoc test where appropriate.

Results

Induction of VEGF in alternatively activated DC

Human monocyte-derived DC were matured *in vitro* in the presence of LPS (classically activated DC (CA-DC)) or a combination of LPS and calcitriol, PGE₂, or IL-10 (AA-DC). Mature DC were then evaluated for their proangiogenic potential by measuring the mRNA steady-state levels of VEGF and FGF-2, two potent angiogenic cytokines. Fig. 1*A* shows that by RT-PCR, CA-DC did not express FGF-2 and expressed barely detectable levels VEGF transcripts. Conversely, CA-DC showed increased mRNA levels, compared with immature DC, for TNF- α and CXCL8, two cytokines that are known to be up-regulated during DC maturation (data not shown) (6). Of interest, VEGF mRNA levels were strongly induced in AA-DC generated in the presence of calcitriol, PGE₂, or IL-10, whereas FGF-2 transcript was induced only weakly in the same experimental conditions. As expected, based on previous studies (9), IL-12p40 was inhibited in AA-DC (Fig. 1*A*). The results obtained at the mRNA level were confirmed by ELISA. Induction of VEGF protein production was easily detectable in AA-DC generated in the presence of calcitriol, PGE₂, and IL-10, with IL-10 being the weakest agonist. Conversely, FGF-2 protein




FIGURE 1. VEGF production by alternatively activated DC. *A*, DC were incubated in the absence (iDC) or in the presence of LPS (CA-DC) for 6 h. AA-DC were incubated with LPS in the presence of calcitriol, PGE₂, or IL-10 for 6 h. mRNA expression was analyzed by RT-PCR. *B*, Cytokines were tested by ELISA in supernatants of DC incubated for 24 h. Data are expressed as mean \pm SEM ($n = 3-6$); *, $p < 0.05$ by Student's *t* test.

levels were undetectable in all the experimental conditions used (Fig. 1*B*). Neither VEGF nor FGF-2 was released by immature DC. TGF- β , a cytokine known for its ability to promote angiogenesis and tissue repair (10), was inactive in inducing VEGF production by DC (data not shown). Collectively, these results show that AA-DC are characterized by the production of high levels of VEGF, a potent proangiogenic cytokine.

The effect of calcitriol on VEGF production was investigated in the presence of agonists, such as TNF- α , SAC, and CD40L, which induce DC maturation by pathways that are different from that used by LPS. Fig. 2 shows that calcitriol was active in inducing VEGF in all the experimental conditions tested. Parallel experiments performed with PGE₂, rather than calcitriol, provided similar results (data not shown).

Circulating DC comprise two main DC populations: myeloid and plasmacytoid (11). Consistent with the results reported above, blood myeloid DC secreted VEGF in a dose-dependent manner when stimulated with LPS in the presence of calcitriol, although at levels that were lower than those observed with monocyte-derived DC (0.34 \pm 0.2 vs 1.64 \pm 0.53 ng/ml 10⁶/DC at 1 μM calcitriol, respectively). No VEGF production was observed with immature DC of classically activated myeloid blood DC (data not shown). Conversely, plasmacytoid DC did not produce VEGF in any of the experimental conditions tested, including activation with influenza virus in the




FIGURE 2. VEGF production by DC alternatively activated by different maturative stimuli. DC were incubated with different maturative stimuli in the absence (CA-DC) or in the presence of 10^{-6} M calcitriol (AA-DC) for 24 h. VEGF production was evaluated by ELISA. Data are expressed as mean \pm SEM ($n = 3-5$); *, $p < 0.05$; **, $p < 0.01$ by Student's *t* test.

presence of calcitriol or PGE₂ (data not shown). Thus, the production of VEGF is apparently restricted to the myeloid DC subset.

Angiogenic properties of alternatively activated DC

The regulation of VEGF production by AA-DC was further characterized. The effect of calcitriol was concentration dependent (Fig. 3A) and time dependent (Fig. 3B). VEGF is produced in multiple isoforms by alternative splicing of a single gene, with VEGF₁₂₁ and VEGF₁₆₅ being the two most common variants (12). Western blot analysis was performed to identify the nature of the splicing isoforms produced by AA-DC. Fig. 3C shows that two major bands, corresponding to VEGF₁₆₅ and VEGF₁₂₁, were detectable in the supernatants from AA-DC but not LPS-activated DC. VEGF exerts its biological activity on endothelial cells through the interaction with tyrosine kinase receptors, namely VEGFR-1 (also known as Flt-1) and VEGFR-2 (also known as KDR or Flk-1) (12). An endothelial cell line transfected with VEGFR-2 (PAE-KDR) was used to evaluate the biological activity of VEGF-containing AA-DC supernatants. The activation of the MAPK ERK1/2 was used as readout for VEGFR-2 activation. Fig. 3D shows that the conditioned medium of DC matured with LPS in the presence of calcitriol-induced ERK1/2 phosphorylation in PAE-KDR cells, whereas no activation was observed using conditioned medium from immature or LPS-activated DC. ERK1/2 activation in PAE-KDR cells was specifically mediated by VEGFR-2 signaling because AA-DC conditioned medium was inactive in mock-transfected PAE cells (data not shown).

On the basis of the *in vitro* results, proangiogenic activity of AA-DC was investigated *in vivo* using the chicken embryo CAM assay. As shown in Fig. 4 calcitriol-AA-DC exert a potent angiogenic response when delivered on the top of the CAM via an alginate-pellet implant. Conversely, immature or LPS-activated DC (Fig. 4B) do not exert any proangiogenic effect in this assay. To assess the contribution of VEGF to the proangiogenic activity of calcitriol-AA-DC, CAM assay was performed in the presence of a VEGF-blocking Ab or SU5416, a VEGFR-2 inhibitor. As reported in Fig. 4B, AA-DC-induced neo-angiogenesis was reduced by 53% in the presence of a blocking anti-VEGF mAb and by 74% in the presence of SU5416. These results indicate that AA-DC induce angiogenesis *in vivo* mainly through the production of VEGF.




FIGURE 3. Characterization of VEGF production by AA-DC. *A*, DC were incubated in the presence of different concentrations of calcitriol for 24 h. *B*, DC were matured with LPS in the absence (CA-DC) or in the presence of 10^{-6} M calcitriol (AA-DC). *C*, VEGF isoforms present in the supernatants of 24-h treated DC were detected by Western blotting ($n = 3$). *D*, Western blot analysis ($n = 3$) of PAE-KDR cells stimulated with conditioned medium of DC. *, $p < 0.05$; **, $p < 0.01$ by one-way ANOVA with Dunnett's post hoc test.

Discussion

Angiogenesis is a process that characterizes tissue remodeling and repair during the late phase of inflammation (13). The resolution of the inflammatory process is characterized by the presence of anti-inflammatory signals, such as IL-10 and corticosteroids, that induce an "alternative/type 2" state of activation of infiltrating leukocytes (2, 3). This study reports that AA-DC release biologically active concentrations of VEGF, *in vitro*, and possess angiogenic activity *in vivo*.

The production of VEGF was selectively observed in AA-DC obtained by *in vitro* DC maturation in the presence of calcitriol, PGE₂, or IL-10. Conversely, VEGF was not produced by immature DC nor by DC activated in the presence of the proinflammatory or immune signals LPS, TNF- α , SAC, or CD40L (i.e., CA-DC). It is interesting to note that AA-DC, at variance with CA-DC, are inhibited in their ability to produce IL-12, a cytokine with potent antiangiogenic activity (9). Therefore, it appears that in AA-DC the balance between pro- and antiangiogenic proteins favors angiogenesis.

Two subsets of human circulating blood DC were defined based on the expression of CD11c, namely CD11c⁺ myeloid DC and CD11c⁻ plasmacytoid DC (11). Myeloid DC express




FIGURE 4. In vivo proangiogenic activity of alternatively activated DC. *A*, DC were entrapped in an alginate pellet and placed on top of the CAM of fertilized chicken eggs. After 72 h, CAM were photographed at $\times 20$ magnification. *B*, Where indicated, the alginate pellet contained a monoclonal anti-VEGF Ab or the VEGFR-2 inhibitor SU5416. After 72 h, angiogenic response was graded on an arbitrary scale of 0–4+, with 0 representing no angiogenic response and 4+ representing the strongest activity. Data are expressed as mean \pm SEM ($n = 5$ –8); *, $p < 0.02$; **, $p < 0.01$ by Student's *t* test.

myeloid markers, such as CD13 and CD33, and produce high levels of IL-12 (11). Conversely, plasmacytoid DC have morphology resembling plasma cells, express high levels of CD4, CD62 ligand, and CD123 and produce high levels of IFN- α (11). These two DC subsets have distinct roles in the induction and regulation of immune response. The data reported in this study, showing that VEGF production is restricted to myeloid DC, further points to this dichotomy.

AA-DC release two of the many VEGF-spliced variants, namely VEGF₁₆₅ and VEGF₁₂₁, and, most importantly, AA-DC-derived VEGF is biologically active, as assessed by its ability to activate VEGFR-2. Accordingly, AA-DC, but not immature or CA-DC, have proangiogenic activity in vivo in the chick embryo CAM assay. Although the contribution of additional angiogenic factors cannot be formally excluded, experiments performed in the presence of a VEGF blocking mAb and SU5416, an inhibitor of VEGFR-2 activity, strongly point to VEGF as the major angiogenic factor produced by AA-DC in vivo.

The production of VEGF is known to be induced by hypoxia, by activated oncogenes, and by a variety of cytokines. In osteoblasts, synovial fibroblasts, monocytic THP-1 cells, and murine macrophages, VEGF production is mediated by increased levels of intracellular cAMP (14). It is interesting to note that both PGE₂ and calcitriol induce cAMP accumulation (15, 16). Consistently with these results, we have observed that 8-(4-chlorophenylthio)-adenosine 3',5'-cAMP, a membrane permeable analog of cAMP, induces VEGF production in LPS-activated DC (E. Riboldi and S. Sozzani, unpublished observation). The effect of calcitriol in angiogenesis is currently unclear with both positive and negative effects reported (9). It is likely that these seemingly divergent results may be due to the use of different cell types and to differences in the experimental protocols used.

VEGF is known to inhibit the ability of hemopoietic progenitor cells to differentiate into functional DC (17). VEGF was also reported to inhibit IL-12 production and Th1 differentiation by LPS-activated DC (18). Therefore, VEGF production by DC might be seen as a potential autocrine negative loop of DC functions. This possibility was ruled out in this study by the use of VEGF blocking Abs during the in vitro maturation of AA-DC; in these experimental conditions, the inhibition of VEGF in the supernatants did not change the generation of mature DC (data not shown).

It was shown recently that in DC, IL-10, and PGE₂ up-regulate the production of thrombospondin 1, an inhibitor of angiogenesis (19). Therefore, AA-DC apparently produce both pro- and antiangiogenic cytokines. However, the in vivo proangiogenic activity of AA-DC reported in our study suggests that, at least in our experimental conditions, the balance of these two activities favors angiogenesis.

Signals associated with a type 2-polarized immune response (IL-4, IL-10, IL-13, calcitriol, and PGE₂) are known to be induced during the resolution phase of inflammation and to be responsible for the inhibition of inflammatory cytokines, the promotion of tissue remodeling and repair, the scavenging of cellular debris, and the inhibition of Th1 responses (2). Type 2-polarizing signals are also produced in other pathological conditions, including cancer (20). Solid tumors are infiltrated by DC that usually lack the phenotype of CA-DC (2, 3). Deregulated VEGF expression has been implicated in the development of solid tumors by supporting tumor angiogenesis (12). The data presented in this study suggest that within the tumor microenvironment AA-DC may represent a source of angiogenic factors contributing to tumor neo-vascularization and growth.

DC activated in the presence of anti-inflammatory agents as calcitriol or IL-10 are known to have tolerogenic properties and a reduced proinflammatory potential (3, 21). This study extends these observations providing evidence that AA-DC also possess a proangiogenic activity in vitro and in vivo through the production of VEGF.

Acknowledgments

We thank Felice De Ceglie for help in the preparation of digital art.

Disclosures

The authors have no financial conflict of interest.

References

- Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. *Nature* 392: 245–252.
- Mantovani, A., S. Sozzani, M. Locati, P. Allavena, and A. Sica. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. *Trends Immunol.* 23: 549–555.
- Goerdts, S., and C. E. Orfanos. 1999. Other functions, other genes: alternative activation of antigen-presenting cells. *Immunity* 10: 137–142.
- Strieter, R. M., J. A. Belperio, R. J. Phillips, and M. P. Keane. 2004. CXC chemokines in angiogenesis of cancer. *Semin. Cancer Biol.* 14: 195–200.
- Frantz, S., K. A. Vincent, O. Feron, and R. A. Kelly. 2005. Innate immunity and angiogenesis. *Circ. Res.* 96: 15–26.
- Vulcano, M., S. Dusi, D. Lissandrini, R. Badolato, P. Mazzi, E. Riboldi, E. Borroni, A. Calleri, M. Donini, A. Plebani, et al. 2004. Toll receptor-mediated regulation of NADPH oxidase in human dendritic cells. *J. Immunol.* 173: 5749–5756.
- Baldanzi, G., S. Mitola, S. Cutrupi, N. Filigheddu, W. J. van Blitterswijk, F. Sinigaglia, F. Bussolino, and A. Graziani. 2004. Activation of diacylglycerol kinase α is required for VEGF-induced angiogenic signaling in vitro. *Oncogene* 23: 4828–4838.

8. Leali, D., P. Dell'Era, H. Stabile, B. Sennino, A. F. Chambers, A. Naldini, S. Sozzani, B. Nico, D. Ribatti, and M. Presta. 2003. Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. *J. Immunol.* 171: 1085–1093.
9. Penna, G., and L. Adorini. 2000. $1\alpha,25$ -Dihydroxyvitamin D_3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. *J. Immunol.* 164: 2405–2411.
10. Roberts, A. B., M. B. Sporn, R. K. Assoian, J. M. Smith, N. S. Roche, L. M. Wakefield, U. I. Heine, L. A. Liotta, V. Falanga, J. H. Kehrl, et al. 1986. Transforming growth factor type β : rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. *Proc. Natl. Acad. Sci. USA* 83: 4167–4171.
11. Colonna, M., G. Trinchieri, and Y. J. Liu. 2004. Plasmacytoid dendritic cells in immunity. *Nat. Immunol.* 5: 1219–1226.
12. Ferrara, N., H. P. Gerber, and J. LeCouter. 2003. The biology of VEGF and its receptors. *Nat. Med.* 9: 669–676.
13. Singer, A. J., and R. A. Clark. 1999. Cutaneous wound healing. *N. Engl. J. Med.* 341: 738–746.
14. Harada, S., J. A. Nagy, K. A. Sullivan, K. A. Thomas, N. Endo, G. A. Rodan, and S. B. Rodan. 1994. Induction of vascular endothelial growth factor expression by prostaglandin E_2 and E_1 in osteoblasts. *J. Clin. Invest.* 93: 2490–2496.
15. Falkenstein, E., H. C. Tillmann, M. Christ, M. Feuring, and M. Wehling. 2000. Multiple actions of steroid hormones: a focus on rapid, nongenomic effects. *Pharmacol. Rev.* 52: 513–556.
16. Regan, J. W. 2003. EP2 and EP4 prostanoid receptor signaling. *Life Sci.* 74: 143–153.
17. Gabrilovich, D. I., H. L. Chen, K. R. Girgis, H. T. Cunningham, G. M. Meny, S. Nadaf, D. Kavanaugh, and D. P. Carbone. 1996. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. [Published erratum appears in 1996 *Nat. Med.* 2: 1267.] *Nat. Med.* 2: 1096–1103.
18. Takahashi, A., K. Kono, F. Ichihara, H. Sugai, H. Fujii, and Y. Matsumoto. 2004. Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. *Cancer Immunol. Immunother.* 53: 543–550.
19. Doyen, V., M. Rubio, D. Braun, T. Nakajima, J. Abe, H. Saito, G. Delespesse, and M. Sarfati. 2003. Thrombospondin 1 is an autocrine negative regulator of human dendritic cell activation. *J. Exp. Med.* 198: 1277–1283.
20. Yamamura, M., R. L. Modlin, J. D. Ohmen, and R. L. Moy. 1993. Local expression of anti-inflammatory cytokines in cancer. *J. Clin. Invest.* 91: 1005–1010.
21. Adorini, L., N. Giarratana, and G. Penna. 2004. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. *Semin. Immunol.* 16: 127–134.